Keywords: epo, angiotech, patent, decision, unchallenged, european, office

EPO Angiotech patent decision unchallenged

Article | 15 August 2005

The decision of the European Patent Office to maintain the validity of Canadian firm Angiotech Pharmaceuticals' paclitaxel-eluting stent patent (Patent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Paclitaxel

Taxol

Go to drug listing